Comparison of the effect of gonadotropin-releasing hormone analog (Diphereline) and Cabergoline (Dostinex) treatment on uterine myoma regression

Saudi Medical Journal

Volumn 28, Issue 3, 2007, Pages 445-450

  Melli, Manizheh Sayyah ^a   Farzadi, Laya ^a   Madarek, Elaheh O S ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DIPHERELINE; GONADORELIN AGONIST; UNCLASSIFIED DRUG;

ADULT; AMENORRHEA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HOT FLUSH; HUMAN; IRAN; JOINT STIFFNESS; MAJOR CLINICAL STUDY; MOOD CHANGE; MUSCLE STIFFNESS; NAUSEA; PELVIS PAIN SYNDROME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TUMOR REGRESSION; TUMOR VOLUME; UNIVERSITY HOSPITAL; UTERUS MYOMA; VAGINAL DRYNESS; VOMITING;

ADULT; BIOPSY, NEEDLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERGOLINES; FEMALE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFUSIONS, INTRAVENOUS; LEIOMYOMA; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 34247201112     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Rein MS. Advances in uterine leiomyoma research: the progesterone hypothesis. Perspect 2000; 108: 791-793.
2. Di Lieto A, De Falco M, Staibano S, Iannotti F, Scaramellino M, Salvatore G, et al. Effects of gonadotropin-releasing hormone agonists on uterine volume and vasculature and on the immunohistochemical expression of basic fibroblast growth Factor (bFGF) in uterine leiomyomas. Int J Gynecol Pathol 2003; 22: 353-358.
3. Lefebvre G, Vilos G, Allaire C, Jeffrey J, Arneja J, Birch C, et al. Clinical Practice Gynaecology Committee, Society for Obstetricians and Gynaecologists of Canada. The management of uterine leiomyomas. J Obstet Gynaecol Can 2003; 25: 396-418.
4. Soon-Cen H, Ming-Jer T, Ya-Min C, Keng-Fu H, Chung-Liang H, Cheng-Yang C. Enhanced Polyadenosine Diphosphate-Ribosylation in Gonadotropin-Releasing Hormone Agonist-Treated Uterine Leiomyoma. The Journal of Clinical Endocrinology & Metabolism 2003; 88: 5009-5016.
5. Schally AV. LH-RH analogues I. Their impact on reproductive medicine. Gynecol Endocrinol 1999; 13: 401-409.
6. Ito F, Kawamura N, Ichimura T, Tsujimura A, Ishiko O, Ogita S. Infrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after GnRH-agonist treatment. Fertil Steril 2001; 75: 125-130.
7. Weeks AD, Duffy SR, Walker JJ. Uterine ultrasonographic changes with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol 1999; 180: 8-13.
8. Wang Y, Matsuo H, Kurachi O, Maruo T. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells. Eur J Endocrinol 2002; 146: 447-456.
9. Mizutani T, Sugihara A, Nakamuro K, Terada N. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate). J Clin Endrocrinol Metab 1998; 83: 1253-1255.
10. Deligdisch L, Hirschmann S, Altchek A. Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata. Fertil Steril 1997; 67: 837-841.
11. Nowak RA, Mora S, Diehl T, Rhoades AR, Stewart EA. Prolactin is an autocrine or paracrine growth factor for human myometrial leiomyoma cells. Gynecol Obset 1999; 48: 127-132.
12. Bole-Feysot C. Prolactin and its receptor, actions, signal transduction pathways and phenot Prolactin and its receptor, actions, signal transduction pathways and phenotpes, observedin PRL receptor knockout mice. Endoc Rev 1998; 19: 225.
13. McClean G, McCluggage WG. Unusual morphologic features of uterine leiomyomas treated with gonadotropin-releasing hormone agonists: massive lymphoid infiltration and vasculitis. Int J Surg Pathol 2003; 11: 339-344.
14. Resta LF, Orsini G, Laricchia L, Piscitelli D, Fiore MG. Morphometric and histological evaluation of uterine leiomyomas treated with GnRH agonists or progestational agents. Pathologica 2004; 96: 35-41.
15. Mizutani T, Sugibara A, Honma H, Komura H, Nakamuro K, Terada N. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropine-releasing hormone agonist therapy. Gynecol Endocrinol 2005; 20: 80-83.
16. Pairleitner H, Steiner H, Hasenoehrl G, Staudach A. Three-dimensional power Doppler sonography: imaging and quantifying blood flow and vascularization. Ultrasound Obstet Gynecol 1999; 14: 139-143.
17. Cheng YM, Chou CY, Huang SC, Lin HC. Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists. Br J Obstet Gynaecol 2001; 108: 95-102.
18. Takeuchi H, Kobori H, Kikuchi I, Sato Y, Mitsuhashi N. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis. J Obstet Gynaecol Res 2000; 26: 325-331.